THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON METABOLIC AND REPRODUCTIVE OUTCOMES IN POLYCYSTIC OVARY SYNDROME

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterised by a constellation of reproductive, metabolic, and hormonal abnormalities. This review evaluates the mechanism of action and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing PCOS by analysing relevant studies from multiple databases. The methodological approach involved systematic screening of studies assessing the impact of GLP-1RAs on metabolic parameters and hormonal profiles with comparisons drawn against the standard therapy of Metformin. The selected studies demonstrated that GLP-1RAs effectively improved insulin sensitivity, promoted weight reduction, and enhanced the hormonal profile in women with PCOS. However, variations in study design, sample sizes, and treatment durations posed challenges to direct comparison. Despite promising evidence supporting the metabolic and reproductive benefits of GLP-1RAs in PCOS, long-term data on safety and sustained efficacy remain limited. Further large-scale randomized controlled trials are needed to establish standardized treatment protocols and evaluate the long-term impact of these agents. This review highlights the potential of GLP1RAs as an emerging therapeutic option in the comprehensive management of PCOS